Human Integrin alpha V beta 3 Alexa Fluor® 647-conjugated Antibody
Human Integrin alpha V beta 3 Alexa Fluor® 647-conjugated Antibody Summary
Human Integrin alpha V (Phe31-Val992) and Human Integrin beta 3 (Gly27-Asp718)
Accession # NP_002201 and AAA52589
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: Integrin alpha V beta 3
Integrin alpha V beta 3 together with alpha IIb beta 3, constitutes the only known beta 3 Integrins (1‑3). The non‑covalent heterodimer of 170 kDa alpha V/CD51 and 93 kDa beta 3/CD61 subunits shows wide expression, notably by endothelial cells and osteoclasts (2‑4). Each subunit has a transmembrane sequence and a short cytoplasmic tail connected to the cytoskeleton. Active cell surface alpha V beta 3 adheres to matrix proteins including vitronectin, fibronectin, fibrinogen and thrombospondin (2, 3). The ligand binding site of alpha V beta 3 is in the N‑terminal head region, formed by interaction of the beta 3 vWFA domain with the alpha V beta‑propeller structure (4). The alpha V subunit contributes a thigh and a calf region, while the beta 3 subunit contains a PSI domain and four cysteine‑rich I‑EGF folds. The alpha V subunit domains termed thigh, calf‑1 and calf‑2 generate a “knee” region that is bent when the alpha V beta 3 is in its constitutively inactive state. Activation, either by “inside out” signaling or by Mg2+ or Mn2+ binding, extends the Integrin to expose its ligand binding site (1, 4). The 962 aa human alpha V ECD(11) shares 92‑95% aa sequence identity with mouse, rat and bovine alpha V while the 685 aa human beta 3 ECD(12) shares 95% aa identity with equine and canine, and 89‑92% aa identity with mouse, rat and porcine beta 3. Two splice variants of beta 3 (b and c) diverge over the last 21 amino acids (aa) and lack cytoplasmic phosphorylation sites (5, 6). Another beta 3 splice variant diverges after the vWFA domain, producing a soluble 60 kDa form in platelets and endothelial cells (7). alpha V beta 3 is essential for the maturation of osteoclasts and their binding and resorption of bone; it also, however, promotes their apoptosis (8, 9). M‑CSF R and alpha V beta 3 share signaling pathways during osteoclastogenesis, and deletion of either molecule causes osteopetrosis (8, 9). alpha V beta 3 is involved in several other signaling pathways by direct interaction with receptor tyrosine kinases and ligands. For example, it cooperates with endothelial cell VEGF R2 in angiogenesis, and with IGF‑1 to promote cancer cell proliferation and invasiveness (13, 14). Also, cell entry of several viruses is mediated by alpha V beta 3 (4, 10).
- Hynes, R. O. (2002) Cell 110:673.
- Serini, G. et al. (2006) Exp. Cell Res. 312:651.
- Ross, F. P. and S. L. Teitelbaum (2005) Immunol. Rev. 208:88.
- Xiong, J. et al. (2001) Science 294:339.
- Kumar, C. S. et al. (1987) J. Biol. Chem. 272:16390.
- vanKuppevelt, H. et al. (1989) Proc. Natl. Acad. Sci. USA 86:5415.
- Djaffar, I. et al. (1994) Biochem. J. 300:69.
- McHugh, K. P. et al. (2000) J. Clin. Invest. 105:433.
- Faccio, R. et al. (2003) J. Clin. Invest. 111:749.
- Chu, J. J. and M. Ng (2004) J. Biol. Chem. 279:54533.
- Suzuki, S. et al. (1987) J. Biol. Chem. 262:14060.
- Fitzgerald, L. A. et al. (1987) J. Biol. Chem. 262:3936.
- Somanath, P.R. et al. (2009) Angiogenesis 12:177.
- Saegusa, J. et al. (2009) J. Biol. Chem. 284:24106.
Product Datasheets
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human Integrin alpha V beta 3 Alexa Fluor® 647-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human Integrin alpha V beta 3 Alexa Fluor® 647-conjugated Antibody and earn rewards!
Have you used Human Integrin alpha V beta 3 Alexa Fluor® 647-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image